Oncolys BioPharma Inc. (4588.T)
JPY 528.0
(0.19%)
JPY 528.0
(0.19%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -1.92 Billion JPY | -66.45% |
| 2022 | -1.14 Billion JPY | 22.28% |
| 2021 | -1.6 Billion JPY | 13.08% |
| 2020 | -2.08 Billion JPY | -222.2% |
| 2019 | -901.53 Million JPY | 56.58% |
| 2018 | -1.22 Billion JPY | -13.19% |
| 2017 | -1.08 Billion JPY | -28.25% |
| 2016 | -909.4 Million JPY | -1.27% |
| 2015 | -833.33 Million JPY | -17.66% |
| 2014 | -716.27 Million JPY | -17.06% |
| 2013 | -613.21 Million JPY | -723.42% |
| 2012 | -75.21 Million JPY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -378.87 Million JPY | 45.34% |
| 2024 Q2 | -414.49 Million JPY | -7.32% |
| 2023 Q4 | -617.34 Million JPY | -53.44% |
| 2023 FY | - JPY | -66.45% |
| 2023 Q1 | -322.23 Million JPY | -4.75% |
| 2023 Q2 | -543.42 Million JPY | -68.64% |
| 2023 Q3 | -402.34 Million JPY | 25.96% |
| 2022 FY | - JPY | 22.28% |
| 2022 Q2 | -239.81 Million JPY | 31.24% |
| 2022 Q1 | -348.76 Million JPY | 44.98% |
| 2022 Q4 | -307.62 Million JPY | -17.03% |
| 2022 Q3 | -262.86 Million JPY | -9.61% |
| 2021 Q3 | -326.79 Million JPY | -9.58% |
| 2021 Q4 | -633.84 Million JPY | -93.96% |
| 2021 Q1 | -348.69 Million JPY | 35.01% |
| 2021 Q2 | -298.21 Million JPY | 14.48% |
| 2021 FY | - JPY | 13.08% |
| 2020 Q3 | -878.59 Million JPY | -133.29% |
| 2020 Q4 | -536.56 Million JPY | 38.93% |
| 2020 FY | - JPY | -222.2% |
| 2020 Q2 | -376.6 Million JPY | -32.48% |
| 2020 Q1 | -284.28 Million JPY | 11.07% |
| 2019 FY | - JPY | 56.58% |
| 2019 Q1 | -358.63 Million JPY | -8.57% |
| 2019 Q3 | -315.12 Million JPY | -454.98% |
| 2019 Q2 | 88.77 Million JPY | 124.75% |
| 2019 Q4 | -319.66 Million JPY | -1.44% |
| 2018 Q3 | -258.47 Million JPY | 21.4% |
| 2018 Q4 | -330.31 Million JPY | -27.79% |
| 2018 Q2 | -328.83 Million JPY | -6.19% |
| 2018 FY | - JPY | -13.19% |
| 2018 Q1 | -309.67 Million JPY | -0.03% |
| 2017 Q4 | -309.58 Million JPY | -19.58% |
| 2017 FY | - JPY | -28.25% |
| 2017 Q1 | -240.88 Million JPY | -40.15% |
| 2017 Q2 | -274.55 Million JPY | -13.98% |
| 2017 Q3 | -258.88 Million JPY | 5.71% |
| 2016 Q4 | -171.88 Million JPY | 36.11% |
| 2016 Q3 | -269.01 Million JPY | -16.66% |
| 2016 Q1 | -184.67 Million JPY | 27.47% |
| 2016 FY | - JPY | -1.27% |
| 2016 Q2 | -230.59 Million JPY | -24.86% |
| 2015 Q1 | -202.74 Million JPY | 29.72% |
| 2015 FY | - JPY | -17.66% |
| 2015 Q4 | -254.6 Million JPY | -31.97% |
| 2015 Q3 | -192.92 Million JPY | 3.62% |
| 2015 Q2 | -200.17 Million JPY | 1.27% |
| 2014 FY | - JPY | -17.06% |
| 2014 Q2 | -179.65 Million JPY | -73.73% |
| 2014 Q3 | -157.92 Million JPY | 12.09% |
| 2014 Q4 | -288.48 Million JPY | -82.67% |
| 2014 Q1 | -103.41 Million JPY | 64.61% |
| 2013 FY | - JPY | -723.42% |
| 2013 Q4 | -292.17 Million JPY | 0.0% |
| 2012 FY | - JPY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 958.1 Million JPY | 301.408% |
| PRISM BioLab Co.,LTD | -488.13 Million JPY | -295.322% |
| GNI Group Ltd. | 14.48 Billion JPY | 113.319% |
| Linical Co., Ltd. | 1.24 Billion JPY | 254.718% |
| Trans Genic Inc. | 240.95 Million JPY | 900.861% |
| MEDINET Co., Ltd. | -1.35 Billion JPY | -42.323% |
| Soiken Holdings Inc. | -583.2 Million JPY | -230.876% |
| Cytori Cell Research Institute, Inc. | -603.09 Million JPY | -219.967% |
| AnGes, Inc. | -8.86 Billion JPY | 78.22% |
| OncoTherapy Science, Inc. | -1.28 Billion JPY | -50.113% |
| Nxera Pharma Co., Ltd. | -7.39 Billion JPY | 73.92% |
| Immuno-Biological Laboratories Co., Ltd. | 128.1 Million JPY | 1606.312% |
| NanoCarrier Co., Ltd. | -863 Million JPY | -123.603% |
| Carna Biosciences, Inc. | -1.09 Billion JPY | -76.747% |
| CanBas Co., Ltd. | 53.65 Million JPY | 3696.747% |
| D. Western Therapeutics Institute, Inc. | -775.59 Million JPY | -148.803% |
| RaQualia Pharma Inc. | -111.8 Million JPY | -1626.005% |
| Chiome Bioscience Inc. | -1.21 Billion JPY | -59.25% |
| Kidswell Bio Corporation | -1.38 Billion JPY | -39.75% |
| PeptiDream Inc. | 7.37 Billion JPY | 126.162% |
| Ribomic Inc. | -1.01 Billion JPY | -90.582% |
| SanBio Company Limited | -4.52 Billion JPY | 57.355% |
| Healios K.K. | -3 Billion JPY | 35.827% |
| BrightPath Biotherapeutics Co., Ltd. | -1.16 Billion JPY | -65.527% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -1.39 Billion JPY | -38.521% |
| Delta-Fly Pharma, Inc. | -1.4 Billion JPY | -37.638% |
| StemRIM | -2.03 Billion JPY | 5.035% |
| CellSource Co., Ltd. | 1.3 Billion JPY | 247.706% |
| FunPep Company Limited | -952 Million JPY | -102.699% |
| Kringle Pharma, Inc. | -888.76 Million JPY | -117.121% |
| Stella Pharma Corporation | -723.85 Million JPY | -166.586% |
| TMS Co., Ltd. | -937 Million JPY | -105.944% |
| Noile-Immune Biotech Inc. | -775.39 Million JPY | -148.867% |
| Cuorips Inc. | -518 Million JPY | -272.527% |
| K Pharma,Inc. | 366.05 Million JPY | 627.154% |
| Takara Bio Inc. | 8.02 Billion JPY | 124.049% |
| ReproCELL Incorporated | 8.24 Million JPY | 23504.378% |
| PhoenixBio Co., Ltd. | 87.93 Million JPY | 2294.377% |
| StemCell Institute Inc. | 534.35 Million JPY | 461.126% |
| Japan Tissue Engineering Co., Ltd. | 244.81 Million JPY | 888.227% |
| CellSeed Inc. | -836.51 Million JPY | -130.682% |